Monogram gets HIV test boost on Pfizer's news
This article was originally published in Clinica
Monogram Biosciences has moved closer to marketing its HIV test for predicting response to a new type of drug being developed by Pfizer, after the pharmaceutical was given a favourable recommendation for approval by US FDA advisors. The agency's antiviral drugs advisory committee voted unanimously (12-0) to recommend that the drug, maraviroc, be approved for use along with other antiretroviral agents for treatment-experienced adults infected with CCR5-tropic HIV-1. Although not bound by its advisors' recommendations, the FDA usually follows them.